Please ensure Javascript is enabled for purposes of website accessibility

The Medicines Company Surges on Positive Drug Trial Results

By Mark Prvulovic - Oct 1, 2019 at 12:24PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company's flagship cholesterol treatment shows major potential.

The Medicines Company (MDCO) announced last week that recent trial data showed positive results for its flagship cholesterol drug, inclisiran. Shares of the company, which has a $3.82 billion market cap, shot up 9.3% in response to the news, and although the stock has given back most of those gains since then, it's still a very encouraging piece of news for the biotech company.

Since the company sold its infectious disease assets back in 2017, The Medicines Company has placed essentially all of its eggs in one basket. This seems to have been a good move, as the drug candidate seems to have an increasingly optimistic pathway to eventual approval by the FDA.

Cholesterol test results displayed on a sheet of paper alongside a stethoscope and some pills.

IMAGE SOURCE: GETTY IMAGES.

What happened?

The Medicines Company, alongside its partner, Alnylam Pharmaceuticals (ALNY -1.21%), has been working on developing a treatment for patients with high cholesterol for years. Specifically, inclisiran is meant to lower LDL cholesterol in patients who are suffering from cardiovascular disease, as well as patients with genetic disorders such as heterozygous familial hypercholesterolemia, an inheritable condition that causes high cholesterol. As an RNA therapy, inclisiran helps patients by influencing the body's protein-manufacturing mechanisms to inhibit the production of LDL cholesterol -- also known as the bad cholesterol -- in the body.

In an announcement last week, the company confirmed that its phase 3 clinical study, ORION-10, had met all of its primary and secondary endpoints of lowering LDL levels in patients during the trial's duration. At the same time, there were no health consequences in terms of kidney or liver abnormalities, something that falls in line with the company's previous studies and reconfirmed the lack of significant side effects of taking inclisiran.

What this means for The Medicines Company

Overall, this is excellent news for The Medicines Company, with some analysts already regarding inclisiran as an easy win.

CEO Mark Timney said:

The results seen in ORION-10 again demonstrate inclisiran's outstanding efficacy, tolerability and safety. This is further validation of the potential of this first and only investigational cholesterol-lowering therapy in the siRNA class to transform the treatment of cardiovascular disease for millions of people with ASCVD [atherosclerotic cardiovascular disease].

Although there is a fair amount of competition in the cholesterol-lowering space, including Repatha from Amgen (AMGN 1.08%), the overall market is large enough that there's plenty of room for competitors. One-third of patients with high cholesterol and plaque-induced arterial blockage don't see significant improvement on a class of drugs called statins and other mainstream cholesterol drugs. That means that out of the 35 million or so patients prescribed statins in the U.S., 11.7 million will require alternative drugs or treatments to get their LDL cholesterol under control.

Cholesterol-lowering drugs such as statins are predicted to be a $22.6 billion market by 2022. Even if only one-third or one-fifth of all patients switch from statins to alternative drugs such as inclisiran, the potential market size of these treatments would easily be between $5 billion and $10 billion.

Further positive developments

Back in December 2018, the company announced it appointed Timney as its new CEO. His previous experience includes working at Merck (MRK -0.46%), where he was involved in cardiovascular product launches for the pharmaceutical giant. This experience fits perfectly with The Medicines Company as the firm transitions from research and development to preparing for an eventual launch. At the moment, regulatory submissions for the cholesterol drug are expected to take place sometime in Q4 2019.

From a financial perspective, The Medicines Company is also in a good position. As of June 30, 2019, the company has $319.3 million in cash or cash equivalents, which is enough to last around nine more months, according to management's estimates. While these reserves won't last forever, it is easy to see the company pursuing additional fundraising activities if it needs to shore up its position.

Overall, prospects seem quite good for the company as well as for its stock. While investors can't ignore the fact that the FDA still needs to approve the drug, and anything can happen in the meanwhile, The Medicines Company seems to have a bright future ahead of it.

Mark Prvulovic has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Alnylam Pharmaceuticals. The Motley Fool recommends Amgen. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

The Medicines Company Stock Quote
The Medicines Company
MDCO
Merck & Co., Inc. Stock Quote
Merck & Co., Inc.
MRK
$90.60 (-0.46%) $0.42
Amgen Inc. Stock Quote
Amgen Inc.
AMGN
$251.08 (1.08%) $2.69
Alnylam Pharmaceuticals, Inc. Stock Quote
Alnylam Pharmaceuticals, Inc.
ALNY
$231.01 (-1.21%) $-2.84

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
400%
 
S&P 500 Returns
128%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/16/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.